

SUBJECT INDEX

A

ABCB1
drug resistance gene, 327–28
ABCG1, 20–21
ABCG2, 381–99
ABCG2/BCRP, 381–99
cancer and, 391–92, 395
dimerization, 390
drug resistance and, 391–92
function of, 389–94
modulation of function, 394–97
significance of variants, 397–98
stem cells and, 387–88
structure of, 383, 389–91
subcellular localization of, 389–91
substrates, 393–97
tissue distribution of, 386–87
Accessory proteins
for G proteins, 151–73
Activator protein-1 (AP-1)
redox sensitive, 221
Activators of G protein
signaling (AGS)
proteins, 151–53, 155–60, 163–65, 167–73
Acute lymphoblastic
leukemia (ALL), 317–40
Acute myeloid leukemia
(AML), 317–40
chemoresistance and, 391–92
Adenosine diphosphate
(ADP)

platelet aggregation and, 287–88
platelet responsiveness to, 284–85
platelets and, 277–64
Adenosine triphosphate
(ATP)
platelets and, 279–82
P2X receptor and, 278
thrombus formation and, 279
Adenosine triphosphate
(ATP)-binding cassette
(ABC), 327
Adenosine triphosphate
(ATP)-binding cassette
(ABC) transporter
ABCG2/BCRP, 381–99
Adenosine triphosphate
(ATP)-binding cassette
(ABC) transporter A1
(ABCA1) gene
atherosclerosis and, 7
liver X receptor (LXR) and, 7, 13, 15, 19, 20, 25–26
Adenoviral infections
CYP regulation and, 126
Adipose tissue
inflammation within, 4
ADP
See Adenosine diphosphate
(ADP)
Age
flavin-containing
monooxygenase (FMO)
and, 83–85
Amino acid
ABCG2 and, 397
Androgen receptor
ABCG2 and, 385
Angiogenesis

platelets and, 277
Angiotensin-converting
enzyme inhibition
(ACEI), 261–62
Angiotensin receptor blockers
(ARB), 261
Anticancer strategy
ABCG2 and, 395–97
Antibesity drugs
CB1 antagonists as, 106–7
Antioxidants
CYP activity and, 128
Antiplatelet compounds
P2Y₁ receptor as target of, 288–90
Antiplatelet drugs, 291
Antithrombotic drugs, 279
platelet P2 receptors and, 285–86
P2Y₁₂ receptor and, 285–86
Antitumor activity
of proteasome inhibitors, 205
Antitumor agents
proteasome inhibitors as, 193–94
Antitumor effects
of proteasome inhibitors, 195–97
Arterial intima
atherosclerosis and, 2
Aryl hydrocarbon receptor
(AHR), 42
CYPs and, 44, 46
humanized mice, 52–53
Ascorbic acid
antioxidant, 260
Aspirin, 291
clopidogrel with, 290

COX inhibitor, 279

A

Atherogenesis
metabolic syndrome and, 3–4

Atherosclerosis, 278
development of, 1–3
endothelial nitric oxide synthase (eNOS) and, 256–57
risk factors and, 3–4

Atherosclerotic plaque
rupture
platelets and, 277

ATP
See Adenosine triphosphate (ATP)

B

Bcl-2 family members
proteasome
inhibitor-mediated apoptosis and, 196

BCRP/ABCG2
cloning, 382–83

Bilirubin, 425

Biliverdin, 425

Bioinformatics, 321

Blood platelets
P2 receptors and, 277–92

Bortezomib, 192, 195–97
anthracycline and, 200
antitumor activity, 193–94
cancer treatments with, 198
clinical studies, 189, 192, 200–6
combination therapies with, 198
hematologic malignancies and, 202
myeloma cell lines and, 198
myeloma patients and, 201
pharmacology of, 200–1

Breast cancer
chemoresistance and, 198

Breast cancer-resistance protein, 328

C

c-Jun N-terminal kinase (JNK) pathway
proteasome
inhibitor-mediated apoptosis and, 196

C5a receptor, 501–2

Calcium (Ca)
nitric oxide synthase (NOS) activity and, 239–40

Calcium channel blockers (CCB), 261, 262

Calmodulin, 239–40

Camptothecin, 398
ABCG2 and, 395, 396

Cancer
ABCG2 and, 391–92, 395
anticancer drug resistance, 337–38
flavin-containing monooxygenase (FMO) and, 88
platelets and, 277
proteases and, 301–11
resistance to chemotherapy, 321
therapy
proteasome inhibitors in, 189–206
treatment(s), 197–99
individualization and optimization of, 340

Cannabinoid therapeutics, 101–13

Cannabinoid receptor(s), 101–13
CB1, 101–9, 112
antagonists, 106–9, 111–13
CB2, 101–3, 106, 109–11
agonists, 109–11, 113

Cannabis extracts, 105

Carbon monoxide (CO), 420–22, 428, 429, 431, 432

antiproliferative effects of, 425–26
apoptosis and, 422–23
caveolae and, 430–32
caveolin-1 and, 430–32
cell cycle and, 423–24
as a cellular signaling molecule, 411–32
chronic inhalation of, 430
circadian clock and, 418–20
effect on macrophages, 426–28
effect on T cells, 428–29
HO-derived, 411, 413
neointimal formation and, 426

neuronal PAS domain protein-2 (NPAS-2) and, 418–20

p38 MAPK and, 420–22, 428, 429, 431, 432

receptors
hemoproteins as, 416–20
sensitivity to hypoxia and, 430

soluble guanylyl cyclase (sGC) and, 417–20, 429

Carboplatin, 198

Carcinogens
cytochrome P450 enzymes and, 41

Carcinomas
ABCG2 and, 392

CATCH22 syndrome, 464, 465

Cation channels
nitric oxide (NO) and, 247–48

Caveolae
carbon monoxide (CO) and, 430–32
caveolae-residing proteins, 427–28
endothelial nitric oxide synthase (eNOS) and, 238–39

signaling domain and, 426
Caveolin-1, 430–32
CDC34
 multiple myeloma and, 195
Cell cycle
 carbon monoxide (CO) and, 423–24
 lactacystin arrests, 192–93
 p38 MAPK and, 423–24
Cellular detoxification
 ABCG2 and, 384
Cellular signaling pathways
 CYP regulation and, 128–29
Center for Proteolytic Pathways, 302
Chemokine receptor transmembrane (TM) receptors and, 500–1
Chemoresistance
 proteasome inhibitors and, 197–200
Chemosensitivity
 genomics and, 321
Chemotherapy
 antileukemic, 321–29
 leukemia and, 318
Childhood acute leukemia, 317–40
Cholesterol
 atherosclerosis and, 3, 5–6
 drug therapy for, 6–7
 macrophage/foam cell and, 7–8
 microdomains and, 431
Chronic lymphocytic leukemia (CLL)
 proteasome inhibitors and, 194
Circadian clock
 carbon monoxide (CO) and, 418–20
Cisplatin, 198
Cks1b
 myeloma patients and, 194–95
Clinical drug trials

pharmacogenetic studies and, 340
Clinical trials
 of thienopyridines, 285–86
Clopidogrel, 285
 with aspirin, 290
 clinical trials, 285–86
 resistance, 286–87
Clozapine
 inflammation and, 127
Colon carcinoma cells
 cell growth signaling in, 227–28
Congenital deficiencies
 P2 receptors and, 284
Constitutive androstane receptor (CAR), 42, 44, 46–47
 humanized mice, 54
Constitutively active receptor (CAR)
 ABCG2 and, 384
Coronary artery disease (CAD)
 atherosclerosis, 1
 statins and, 2–3
 vitamin C treatment and, 260
CPT-11
 bortezomib with, 198
Craving
 CB1 antagonists and, 108–9
CREST study, 202
Crohn's disease
 CYP activity and, 126
Cyclooxygenase (COX)
 thrombus formation and, 279
Cyclophosphamide, 198
CYP enzymes
 diabetes and, 88–89
 downregulated in inflammation, 125–27
 drug metabolism by, 43
 flavin-containing monooxygenase (FMO) and, 80–81
 inflammation and, 123–35, 139–40
 mechanisms of regulation, 127–33
 nitric oxide (NO) and, 132–33
 regulation of, 125–32
 role in inflammation response, 133–35
CYP3A4, 44, 45, 47
CYP3A4-humanized mice, 50–51
CYP2D6, 42, 44, 45, 47
CYPD6-humanized mice
 cytochrome P450 and, 47–50
CYP2E1, 45
CYP2E1-humanized mice, 51–52
Cysteine (Cys)/cysteine (CySS), 217
 redox, 225–28
Cytochrome P450 (CYP450), 65
 antileukemic agents and, 322–23
 inflammatory responses and, 134–35
 xenobiotic receptor humanized mice and, 41–56
 xenobiotics and, 43–44
Cytokines
 roles and sources of, 127–28
Cytoplasmic redox couples
 transcription factor regulation and, 221–23

D

Dephosphorylation
endothelial nitric oxide synthase (eNOS) and, 255
Detoxification
 cellular, 384

Dexamethasone
bortezomib and, 202–5

Diabetes
atherosclerosis and, 4
flavin-containing
monooxygenase (FMO)
and, 88–89

Diet
flavin-containing
monooxygenase (FMO)
and, 82–83

Diflomotecan, 398

Dihydrofolate reductase
(DHFR)
methotrexate (MTX)
resistance and, 332

Diseases
flavin-containing
monooxygenase (FMO)
gene family and, 86–90

Dose-limiting toxicities
(DLTs)
bortezomib and, 201

Doxorubicin, 323
bortezomib and, 204
myeloma cell lines and,
198

Dronabinol, 105

Drug development
flavin-containing
monooxygenase (FMO)
and, 81–82
pharmacogenomics and,
340

Drug-drug interactions
adverse, 82–83

Drug metabolism
cytochrome P450s and,
43–44
infection and, 126–27
species differences in, 47

Drug metabolizing enzymes
(DMEs)
inflammation and, 123–40
regulation of, 125–37

Drug reactions, 43

Drug resistance

ABCG2 and, 381–99
anticancer, 337–38
gene expression associated
with, 338–39
membrane transporters
and, 327–29
proteasome inhibitors and,
205

Drug therapy
atherosclerosis and, 3
macrophages as target for,
5–8

Dyslipidemia
endothelial nitric oxide
synthase (eNOS) and,
256–57

E

11S proteasome activator,
191

Embryogenesis
retinoid receptors (RXRs)
and, 459–60

Embryonic stem (ES) cells
ABCG2 and, 388

Endocannabinoid(s), 102–4
neuronal plasticity and,
104–5
signaling system, 102
transport inhibitors, 112

Endoplasmic reticulum (ER)
apoptotic pathways and,
197

Endothelial cells
antithrombotic surface of,
278

Endothelial nitric oxide
synthase(s)(eNOS),
235–64, 431, 432
dephosphorylation and,
255
estrogen and, 252–54, 258
extracellular regulation of,
249–55
G protein-coupled
receptors and, 250–51
high-density lipoprotein
(HDL) and, 257–58
hormones and, 253–54
hypoxia and, 258–59
insulin and, 253
low-density lipoprotein
(LDL) and, 256–57
lysophosphatidic acid
(LPA) and, 251–52
oxidative stress and,
259–60
pathophysiologic states
affecting, 256–60
receptor-independent
pathways of activation,
254
sphingosine 1-phosphate
(S1P) and, 251–52
thrombin and, 254
vascular endothelial growth
factor (VEGF) and,
252–53

Endothelium
nyrosylation and cation
channels in, 247–48

eNOS
See Endothelial nitric
oxide synthase(s) (eNOS)

Enzymes
drug metabolizing enzymes
(DMEs)
inflammation and,
123–40
phase I, 41–43
antineukemic agents and,
322–24
phase 2, 41–42, 135, 139

Epinephrine
binding process, 497–500

Epoxomicin, 192, 193

Estrogen
endothelial nitric oxide
synthase (eNOS) and,
252–54, 258

Estrogen response element
(ERE)
ABCG2 and, 385–86

Eye morphogenesis

neural crest and, 465–66

Ezetimibe, 3

F

Familial adenomatous polyposis (FAP), 88

Fatty acid amino hydrolase (FAAH), 104, 111–12

Fatty streaks atherosclerotic lesion, 1–2

Fibrates, 1, 12, 13, 15–16

Fireflies, 263

Flavin-containing monooxygenase (FMO), 65–90

age and, 83–85

cancer and, 88

catalytic mechanism, 80–81

diabetes and, 88–89

diet and, 82–83

drug development and, 81–82

gender and, 85–86

gene organization, 68–69

genetic variation, 69–71

hemochromatosis and, 88

human, 65–90

hypertension and, 86–87

interindividual differences of, 71–74

nicotine and, 89–90

nomenclature, 66–67

posttranscriptional regulation and, 71

protein structure of, 80–81

regulation, 67–68

smoking and, 89–90

species differences, 67–68

splicing variants, 79–80

transcriptional regulation and, 70–71

X-ray crystallography of, 90

Flavin-containing monooxygenase (FMO)

single nucleotide polymorphisms (SNPs) and 4, 78–79

Flavin-containing monooxygenase (FMO) 1, 74–75

Flavin-containing monooxygenase (FMO) 2, 75–76

Flavin-containing monooxygenase (FMO) 3

disease and, 86–90

interindividual variability in human, 71–74

rare mutations, 77–78

single nucleotide polymorphisms (SNPs) and, 76–78

Flavin-containing monooxygenase (FMO) 5, 78–79

Flavin-containing monooxygenase (FMO) 6

pseudogene, 66

Flavin monooxygenase (FMO), 123, 135

Flow conditions thrombus formation and, 282–83

Flow systems platelet function studies with, 282–83

G

G protein(s) accessory proteins for, 151–73

altered interactions of subunits, 171–72

guanine nucleotide exchange factors (GEFs) and, 155–63, 165–67

G protein-coupled receptor(s) (GPCR), 151–55, 164–66, 168, 170–73

endothelial nitric oxide synthase (eNOS) and, 250–51

ligands for, 250–52

phospholipase C (PLC) and, 363, 366, 372

See also Seven transmembrane receptors (7TM)

G protein-regulated isozymes novel structural features of, 362–64

GAP-43, 155, 156, 164, 167, 172

Gefitinib ABCG2 and, 395–97

Gemcitabine, 198

Gender

flavin-containing monooxygenase (FMO) and, 85–86

Gene(s) expression

drug resistance and, 337–39

profiling, 319–20

treatment response in leukemia and, 334–39

flavin-containing monooxygenase (FMO), 66, 67, 90

age and, 84

organization of, 68–69

pharmacogenomics and, 317–40

Genetic polymorphisms antileukemic chemotherapy and, 321–29

Genetic variation

flavin-containing monooxygenase (FMO) and, 69–71

Genotyping methods, 319

Ghrelin receptor family toggle switch activation and, 502

Glitazones, 16, 21

Glucocorticoid receptor (NR3C1), 333–34

Glucocorticosteroids
acute lymphoblastic leukemia (ALL) and, 333–34

Glutathione (GSH), 222–23, 229
glutathione (GSH)/glutathione disulfide (GSSG), 217, 225–26
nuclear compartmentation of, 217–18

Glutathione S-transferase(s) (GST), 123, 135–36
chemotherapeutic agents and, 324–25

Green fluorescent proteins (GFPs), 218–20, 228

GTPase activity
accessory proteins and, 153, 172

GTPases activating protein (GAP)
phospholipase C (PLC) and, 362

Guanine nucleotide dissociation inhibitors (GDIs), 155–60, 167–68

Guanine nucleotide exchange factor(s) (GEFs), 371

G proteins and, 155–63, 165–67, 172

Ras, 364, 370
signal input for, 167, 173

GW7647, 14–15

H

Haplotypes, 319

Heat shock proteins (HSPs)
proteasome inhibitors and, 199–200, 205

Hematologic malignancies
bortezomib studies and, 204, 206

Heme oxygenase (HO), 411

HO-1, 412
antagonistic induction of, 416
immunity and, 428–29
macrophages and, 426, 428
as a protective gene, 425
synergistic induction of, 414–16
transcriptional regulation of, 414–16
vascular smooth muscle cells and, 425–26

Hemochromatosis
flavin-containing monooxygenase (FMO) and, 88

Hemoproteins
as carbon monoxide receptors, 416–20

Hemostasis, 277, 278

Hepatic transporters
regulation of, 137–39

Hepatocyte nuclear factors (HNFs)
inflammation and, 130

Heterodimers
RXR/RAR, 451–53, 462–64, 466, 467, 469, 470

High-density lipoprotein(s) (HDL)
atherosclerosis and, 2–3
endothelial nitric oxide synthase (eNOS) and, 257–58

peroxisome
proliferator-activated receptor- α (PPAR- α) and, 14

peroxisome
proliferator-activated receptor- δ (PPAR- δ) and, 23

Hormones
endothelial nitric oxide synthase (eNOS) and, 253–54

flavin-containing monooxygenase (FMO) activity and, 70–71

HSP-72
proteasome inhibitors and, 199–200

HSP-90
proteasome inhibitors and, 199–200

Hu/Mu Protein Chip
proteases and, 303

Human flavin-containing monooxygenase (FMO), 65–90

Hydrogen sulfide (H₂S), 411

Hypertension
flavin-containing monooxygenase (FMO) and, 86–87

Hypoxia
endothelial nitric oxide synthase (eNOS) and, 258–59

Hypoxia-inducible factor 1 (HIF-1)
ABCG2 and, 385, 391

Hypoxia-inducible transcription factor (HIF)
ABCG2 and, 388

Hypoxia response elements (HRE)
ABCG2 and, 385

I

Imaging
of tumor proteolysis, 301–11

Imatinib
ABCG2 and, 395–96

Immunity
carbon monoxide (CO) and, 426–29

Infection

drug metabolism and, 126–27
Inflammation
 CYPs downregulated in, 125–27
 drug disposition in, 123–40
 nitrotyrosine and, 249
 p38 MAPK and, 426–28
 phase II enzymes and, 135, 139
 See also Inflammatory response
Inflammatory bowel movement (IBD)
 CYP activity and, 126
Inflammatory response
 role of CYPs in, 133–35
 See also Inflammation
Insulin
 endothelial nitric oxide synthase (eNOS) and, 253
 See also Insulin resistance (IR); Insulin sensitivity; Insulin-sensitizing drugs
Insulin resistance (IR)
 atherosclerosis and, 4
 Insulin sensitivity, 16–18, 24
 Insulin-sensitizing drugs, 16
 Irinotecan, 396–98
Isozymes
 phospholipase C, 355–73

K

Kinase inhibitors
 acute lymphoblastic leukemia (ALL) and, 334
Koshland induced fit model for ligand binding, 504–6

L

Lactacystin, 192–93
Leukemia
 acute
 pharmacogenomics of, 317–40
 treatment response in, 334–39

chronic lymphocytic leukemia (CLL), 194
 outcome prediction, 334–36
Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), 334
Lipopolysaccharide (LPS)
 drug metabolizing enzymes (DMEs) in rats treated with, 125–26, 128–32, 134–37
 hepatic transport systems in rodents treated with, 137–39
Liver X receptor (LXR)
 ATP binding cassette transporter A1 (ABCA1) gene and, 7, 13, 15, 19, 20, 25–26
Low-density lipoproteins (LDL)
 atherosclerosis and, 1–3, 5, 6
drug therapy for
 atherosclerosis and, 5–7
 endothelial nitric oxide synthase (eNOS) and, 256–57
 nitric oxide (NO) synthesis and, 256
 oxidation, 12, 14
 statins and, 261
 torcetrapib and, 2
Lymphoma
 bortezomib and, 202, 203, 205
Lysophosphatidic acid (LPA)
 endothelial nitric oxide synthase (eNOS) and, 251–52
Lysophosphatidylcholine (LPC)
 endothelial nitric oxide synthase (eNOS) and, 256–57

M

Macrophage(s)
 atherogenesis and, 5–8
 atherosclerosis and, 1–2
 carbon monoxide (CO) and, 426–28
 foam cell formation, 15
 gene expression in, 18
 peroxisome proliferator-activated receptors (PPARs) and, 1–27
Major histocompatibility complex (MHC) class I proteasome, 190
MAPK
 See Mitogen-activated protein kinase (MAPK)
Matrix metalloproteinase inhibitors (MMPIs), 301, 302
Matrix metalloproteinases (MMPs)
 cancer and, 301–2
Maximum tolerated dose (MTD)
 bortezomib and, 201, 202
Melphalan
 myeloma and, 198, 205
Membrane transporters
 drug resistance and, 327–29
Mesectodermal derivatives
 retinoic acid receptors (RARs) and, 456, 458–59
Metabolic syndrome
 atherogenesis and, 3–4
 defined, 4
Metabolism
 xenobiotic receptors and, 44, 46–47
Metal centers
 nitric oxide (NO) reactivity with, 241–44
Metal ion site(s)
 transmembrane (TM)

receptors and, 489–90, 500–1

M

Methotrexate (MTX)
acute lymphoblastic leukemia (ALL) and, 331–33

5,10-Methylenetetrahydrofolate reductase (MTHFR)
methotrexate (MTX)
toxicity and, 333

MG-132
treatment of myeloma cells with, 197

Mitochondria
interaction of nitric oxide (NO) with metal centers in, 243
redox states in, 223–24

Mitochondrial nitric oxide synthase (NOS), 243–44

Mitochondrial redox, 215–29
redox sensitive green fluorescent proteins (roGFP) and, 225

Mitogen-activated protein kinase (MAPK)
carbon monoxide (CO) and, 411, 420–22, 432
See also P38
mitogen-activated protein kinase (MAPK)

Mitogen-activated protein kinase (MAPK)
phosphatase (MKP)-1, 200, 205

Mitoxantrone
ABCG2 and, 383, 394
myeloma cell lines and, 198

Mitoxantrone resistance (MXR), 381, 383

Molecular activation mechanism
seven transmembrane receptors (7TM) and, 481–509

Monoacylglycerol (MAG)
lipase, 104, 113

Monod-Wyman-Changeux conformational switch, 504–6

Multidrug resistance 1 (MDRI), 381, 387

Multidrug resistance protein 1 (Mrp1), 381–83, 394, 397

Multidrug resistance proteins (MRP), 327–28

Multiple myeloma
bortezomib and, 189, 192, 202, 204–6
proteasome inhibitors and, 193–96
ubiquitin-proteasome pathway (UPP) and, 194

Myeloma cells
treatment of, 197

N

19S proteasome, 191

Neural crest
eye morphogenesis and, 465–66

Neural crest cells (NCC), 456, 464–65

Neuronal PAS domain protein-2 (NPAS-2)
carbon monoxide (CO) and, 416–20

Neuronal plasticity
endocannabinoids and, 104–5

Neuropathy
bortezomib clinical studies and, 202–3

NF-E2 related factor 2 (Nrf2)
redox sensitive, 222

NG-GPA, 155, 156, 165

Nicotine
flavin-containing monooxygenase (FMO) and, 89–90

Nitric oxide (NO), 411
cardioprotective drugs and, 261–62
caveolin-1 and, 431, 432
covalent interaction with proteins, 244–49
CYP enzymes and, 132–33
extracellular regulation of, 249–55
intracellular regulation of, 237–41
nitrosothiols and, 244–45, 248
novel roles for, 263
oxidative stress and, 259–60
pathophysiologic states affecting, 256–60
pharmacologic intervention in physiology, 260–62
pharmacologic paradigm of action of, 241–49
protein radicals and, 248
reactivity with metal centers, 241–44
soluble guanylate cyclase (sGC) and, 241–42
soluble guanylyl cyclase (sGC) and, 417–18

Nitric oxide synthase (NOS), 235–64
CYP enzymes and, 132–33
drugs affecting, 261–62
expression and
transcription of, 237–38
regulation of, 237–41

Nitrosothiols
nitric oxide (NO) and, 244–45, 248

Nitrosylation
nitric oxide (NO) and, 247–48

Nitrotyrosine
inflammation and, 249

Nitrovasodilator drugs, 260–62

Non-Hodgkin lymphoma (NHL)

bortezomib and, 189, 202–6

NPI-0052

- proteasome inhibitor, 193

NR1C3, 1, 9, 16–22, 25–27

NR1I2, 42

Nuclear compartmentation of glutathione (GSH), 217–18

Nuclear factor-kappa B (NF- κ B)

- proteasome inhibitors and, 195–98
- redox sensitive, 221–22

Nuclear receptors, 8–11

- CYPs and, 46
- regulation of gene expression by, 10

Nuclear redox, 215–29

- measured by Trx1, 220
- new methods to measure, 218–20
- transcription factor regulation and, 221–23

O

Obesity

 - macrophages and, 4

Organogenesis

 - retinoic acid receptors (RARs) and, 454–56

Organotypic models

 - tumor proteolysis and, 301, 309

Oxidative stress, 215–29

 - CYP downregulation by, 128
 - endothelial nitric oxide synthase (eNOS) and, 259–60
 - microcompartmentation of, 228
 - mitochondrial thioredoxin and, 224–25
 - new definition of, 216–17
 - nitric oxide (NO) and, 259–60

plasma membrane and, 225–28

Oxygen sensing, 430

P

p27

 - CDC34 and, 195
 - future cancer therapies and, 195
 - malignant cells and, 194
 - proteasome inhibition and, 197

p53

 - proteasome inhibitors and, 196–97

P-glycoprotein (P-gp)

 - ABCG2 and, 381, 383, 387, 393–96
 - chemoresistance and, 198
 - multidrug resistance gene and, 327

p38 mitogen-activated protein kinase (MAPK)

 - anti-proliferative effect of, 424–26
 - apoptosis and, 422–23
 - carbon monoxide (CO) and, 413, 420–22, 428, 429, 431, 432
 - cell cycle and, 423–24
 - inflammation and, 426–28

P2 receptors

 - inflammation and, 290–92
 - platelet function and, 277–92

PA200

 - proteasome activator, 191

PA700

 - proteasome activator, 191

Palmitoylation

 - nitric oxide synthase (NOS) activity and, 239–40

Pegylated liposomal doxorubicin

 - bortezomib and, 204

Peroxisome

 - proliferator-activated receptor- α (PPAR- α), 1, 9, 12–16, 24–26, 42, 44, 46, 47
 - atherosclerosis and, 14–15
 - downregulation of CYP and, 131
 - humanized mice, 54–55

Peroxisome

 - proliferator-activated receptor- δ (PPAR- δ), 1, 9, 22–26

Peroxisome

 - proliferator-activated receptor- λ (PPAR- λ), 1, 9, 16–22, 25–27

Peroxisome

 - proliferator-activated receptors (PPARs), 1–27
 - structure and function of, 9–10

Pharmacogenomics

 - acute leukemia and, 317–40
 - explained, 320
 - future of, 339–40

Pheophorbide ABCG2 and, 395

Philadelphia

 - chromosome-positive acute lymphoblastic leukemia (ALL), 334

Phosphatidylethanolamine-binding protein (PBP), 155, 156, 166, 167, 172

Phosphatidylinositol-3 kinase (PI3K)

 - ABCG2 and, 390–91
 - endothelial nitric oxide synthase (eNOS) and, 254–55

Phospholipase C (PLC)

 - family of, 358–59
 - isozymes, 355–73
 - structure of, 359–64

Phospholipases

diverging class of, 360–62

Phosphorylation, 133

- endothelial nitric oxide synthase (eNOS) and, 254–55
- nitric oxide synthase (NOS) isoforms and, 240

Plasma membrane

- oxidative stress at, 225–28
- redox signaling at, 225–28

Platelet(s)

- arterial thrombus formation and, 278–79
- refractory state of, 283–84

Platelet P2 receptors, 277–92

- angiogenesis and, 290–92
- atherosclerosis and, 290–92
- inflammation and, 290–92
- targets for antithrombotic drugs, 285–86

POH1

- multiple myeloma and, 194

Polymorphisms

- of P2Y receptors, 284–85
- treatment failure and, 318

Position 482

- ABCG2 and, 397–98

Posttranscriptional regulation

- flavin-containing monooxygenase (FMO) and, 71

Pregnant X receptor (PXR), 42

- CYPs and, 46
- humanized mice, 53–54

Protease activity

- imaging assays and, 302–4

Proteases

- tumors and, 301–11

Proteasome inhibition

- molecular sequelae of, 195–97

Proteasome inhibitor(s)

- antitumor activity of, 205
- as antitumor agents, 193–94

antitumor effect, 195–97

bortezomib, 200–6

cancer therapy, 189–206

chemoresistance to, 199–200

development of, 191–93

sensitize cells to

- therapeutics, 197–99

targets of, 195–97

transformed cells and, 194–95

Protein(s)

- breast cancer-resistance protein, 328
- multidrug resistance proteins (MRP), 327–28
- nitric oxide (NO) covalent interaction with, 244–49
- S-nitrosylation and, 245–47

Protein binding partners

- for G protein subunits, 155–63, 173

Protein kinases

- CYP downregulation and, 129, 133

Protein radicals

- nitric oxide (NO) and, 248

Protein structure

- flavin-containing monooxygenase (FMO) and, 80–81

Proteolysis

- in four dimensions, 307, 309
- migration and invasion and, 307–9
- of misfolded proteins, 197 in three dimensions, 306–7, 309
- tumor
- imaging of, 301–11
- in two dimensions, 305–6
- in vitro by live tumor cells, 304–9

Protoporphyrin

- ABCG2 and, 395, 396

PS-341, 192

See also Bortezomib

P2T receptor, 278

- antagonists, 288

P2X₁

- congenital deficiencies and, 284
- platelet function and, 277, 281–82

P2X₁ receptor

- antiplatelet compounds and, 289–90
- inflammation and, 291
- thrombus formation and, 282

PXR

- ABCG2 and, 384

P2Y₁₂

- competitive antagonists of, 287–88
- congenital deficiencies and, 284
- platelet function and, 277, 280–82

P2Y₁₂ antagonists, 291

P2Y receptor(s)

- platelet function and, 277–82
- polymorphisms of, 284–85
- thrombus formation and, 282–83

P2Y₁ receptor, 290

- angiogenesis and, 291
- antiplatelet compounds and, 288–89
- desensitization, 283–84
- inflammation and, 291
- thrombus formation and, 282–83

P2Y₂ receptor

- angiogenesis and, 291

P2Y₁₂ receptor(s)

- angiogenesis and, 291
- inflammation and, 290–91
- thrombus and, 283–85

Q

Quinone oxidoreductase (NQO1), 323–24

R

Rac

- phospholipase C (PLC) isozymes and, 364–66

Radiation

- combined with bortezomib, 198

Raf kinase interacting protein (RKIP), 155, 156, 166, 167, 172

Ras

- phospholipase C (PLC) and, 366–68, 370–71

Ras family GTPases

- phospholipase C (PLC) isozymes and, 355–73

Redox

- nuclear and
- mitochondrial, 215–29
- signaling, 215–29
- microcompartmentation of, 228
- nuclear and cytoplasmic redox states during, 220–21
- plasma membrane and, 225–28
- signaling and control, 223–25
- states
- mitochondrial, 223–24

Redox sensitive green fluorescent proteins (roGFP), 218–20, 225

Reduced folate carrier (RFC)

- drug resistance and, 328–29

Regulator of G protein signaling (RGS)

- accessory proteins and, 153, 171, 172

Retinal function

- rhodopsin activation

and, 497

Retinaldehyde

- dehydrogenases, 454, 456, 468, 469

Retinoic acid (RA)

- signaling, 451–71

Retinoic acid receptors (RARs), 451–71

- development and, 464–66
- hindbrain segmentation and, 465
- mesectodermal derivatives and, 456, 458–59

Retinoic acid signaling, 451–71

- retinoic acid receptors (RARs) and, 454–64
- rexinoid receptors (RXRs) and, 454–64

Retinoid nuclear receptors, 451–71

Retinoid receptor functions in vitro studies, 452–54

Retinoids, 451

- teratogenicity and, 466–69

Retinol, 451

Rexinoid receptors (RXRs), 451–71

- development and, 460–64

Rho

- phospholipase C (PLC) and, 364–65, 368–70, 372

Rhodopsin

- retinal functions and, 497
- seven transmembrane receptors (7TM) and, 508

Rhodopsin-like seven transmembrane receptors (7TM)

- agonist binding in, 483–86

Ric-8, 155, 157, 166

Rpn11

- multiple myeloma and, 194

S

S-nitrosylation

- endothelial nitric oxide synthase (eNOS) and, 240–41
- protein activity and, 245–47

Schizophrenia

- clozapine and, 127

Selective estrogen receptor modulators (SERMs), 27

Selective PPAR modulators (SPPARMs), 27

Seven transmembrane receptors (7TM), 481–509

- activated through metal ion sites, 489–90
- agonist binding in, 483–86
- dynamic *versus* rigid interfaces, 506–7
- locks and keys for, 502–4
- toggle switch activation of, 481–509

Sex hormones

- ABCG2 and, 385

Shear forces

- thrombus formation and, 282–83

Signal transduction

- accessory and G proteins and, 151–73
- thiol/disulfide redox and, 216–17
- transmembranes and, 488

Single-nucleotide polymorphism(s) (SNPs), 318–19

ABCG2 and, 386, 398

flavin-containing monooxygenase (FMO) and, 69–71, 74–79, 86

Site Directed Drug Discover, 482, 509

Skp2

- future cancer therapies and, 195

SLC19A1

- drug resistance and, 328–29

Smoking
 flavin-containing monooxygenase (FMO) and, 89–90

Soluble guanylate cyclase (sGC)
 nitric oxide (NO) activates, 241–42

Soluble guanylyl cyclase (sGC)
 carbon monoxide (CO) and, 417–20, 429
 caveolin-1 and, 432

Sphingolipids
 microdomains and, 431

Sphingosine 1-phosphate (S1P)
 endothelial nitric oxide synthase (eNOS) and, 251–52

Statins, 261
 atherosclerosis and, 2–3
 coronary artery disease (CAD), 2–3
 drugs in combination with, 3
 peroxisome proliferator-activated receptor (PPAR) agonists and, 27

Stem cells
 ABCG2 in, 387–88

Steroid X receptor (SXR)
 CYPs and, 46

Strokes
 atherosclerosis, 1

Sulfotransferase (SULT), 123, 136

SUMMIT study, 202, 204

T

20S proteasome, 190–92

T cells
 carbon monoxide (CO) and, 428–29

Teratogenecity
 retinoids and, 466–69

Thalidomide
 bortezomib and, 205

Therapeutics
 proteasome inhibitors sensitize cells to, 197–99

Thiazolidinediones (TZDs), 16, 21

Thienopyridine(s), 287
 antithrombotic, 285

Thiopurine
 S-methyltransferase (TPMT), 329–30
 chemotherapeutic agents and, 324–26

Thiopurines
 acute lymphoblastic leukemia (ALL) and, 329–31

Thioredoxin
 mitochondrial, 224–25

Thrombin
 endothelial nitric oxide synthase (eNOS) and, 254

Thrombosis, 277–78
 P2 receptor and, 278
 P2Y₁₂ antagonists and, 288
 P2Y₁ receptor and, 288–89

Thromboxane A₂ (TXA₂)
 thrombus formation and, 279–81

Thrombus formation, 278–79
 flow conditions and, 282–83
 P2 receptors and, 282–83
 platelet activation and, 278–79
 shear forces and, 282–83

Thymidylate synthetase
 acute lymphoblastic leukemia (ALL) and, 333

Ticlopidine, 285

Toggle switch activation
 ghrelin receptor family and, 502
 of seven transmembrane receptors (7TM), 481–509

Torcetrapib, 3

Total parenteral nutrition (TPN)
 flavin-containing monooxygenase (FMO) and, 82–83

Toxins
 cytochrome P450 enzymes and, 41

Transcription factor
 regulation
 nuclear and cytoplasmic redox couples and, 221–23

Transcriptional regulation of CYP enzymes, 129–31

flavin-containing monooxygenase (FMO) and, 70–71

Transformed cells
 proteasome inhibitors and, 194–95

Transmembrane (TM)
 receptors
 main ligand-binding pocket and, 488–91
 movements of, 486–88, 490–96

Trimethylamine (TMA)
 flavin-containing monooxygenase (FMO) and, 66, 69, 70, 72, 73, 76–78, 83, 86–87

Troglitazone, 21

Trx
 mitochondrial, 224

Trx1, 222, 229
 nuclear redox state measured by, 220

Tubulin, 157, 163, 165, 166

Tumor(s)
 ABCG2 and, 392
 bortezomib trial and, 203
 chronic inflammation and, 127
 microenvironment

neoplastic progression and, 309

p
proteolysis imaging of, 301–11
in vivo, 309–10
sensitivity to therapeutics, 197

Tunicamycin
myeloma cells and, 197

Turpentine
animals treated with, 125, 129–30, 137–39

U
Ubiquitin-proteasome pathway (UPP)
malignant transformation and, 194, 205
multiple myeloma and, 194
proteolysis through, 190–91

UDP-glucuronosyltransferase (UGT), 123, 135
chemotherapeutic agents and, 324, 326

Ulcerative colitis
CYP activity and, 126

Unfolded protein response (UPR), 197

V
Vascular endothelial cells
monocyte adhesion to, 226–27

Vascular endothelial growth factor (VEGF)
endothelial nitric oxide synthase (eNOS) and, 252–53

Vitamin A deficiency (VAD)
syndrome, 451–52, 454–59, 463


Vitamin C
antioxidant, 260

Von Willebrand factor (vWF)
platelet activation and, 278–79

X
Xenobiotic receptor
humanized mice
cytochrome P450 and, 41–56

Xenobiotic receptors
metabolism and, 44, 46–47

Xenobiotics
biological mediators in response to, 43–47
CYPs and, 42
cytochrome P450s and, 43–44



CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 42-46

A

Abdel-Rahman SM, 44:111-36
Adams JP, 42:135-63
Aitken AE, 46:123-49
Allio T, 43:125-47
Altman RB, 42:113-33
Ambler SK, 45:657-87
Anders MW, 45:147-76
Anderson RGW, 45:587-603
Anderson KC, 45:465-76
Angers S, 42:409-35
Arav-Boger R, 45:565-85
Arnason JT, 45:203-26
Aschner M, 44:87-110
Atkins WM, 45:291-310
Aweeka F, 44:499-523

B

Baldwin LA, 43:175-97
Bale TL, 44:525-58
Barber DL, 42:527-52
Barnes PJ, 42:81-98
Bearss DJ, 43:359-79
Benz CC, 45:495-528
Besirli CG, 44:451-74
Beutler B, 43:609-28
Bicknell R, 44:219-38
Bieck PR, 45:227-46
Blaschke TF, 44:499-523
Blakely RD, 43:521-44
Blumer JB, 46:151-87
Boekelheide K, 43:125-47
Bogdanffy MS, 43:485-520
Bolt HM, 43:485-520
Bortner CD, 42:259-81
Bouvier M, 42:409-35
Brady AE, 44:559-609

Briggs CJ, 45:203-26
Brown RD, 45:657-87

C

Calabrese EJ, 43:175-97
Caro AA, 44:27-42
Caron MG, 43:261-84
Cashman JR, 46:65-100
Casida JE, 45:247-68
Cavallo-Medved D, 46:301-15
Cederbaum AI, 44:27-42
Chambon P, 46:451-80
Chauhan D, 45:465-76
Chen J-F, 45:385-412
Cheok MH, 46:317-53
Choi AMK, 46:411-49
Chuang D-M, 45:269-90
Cidlowski JA, 42:259-81
Claiborne A, 44:325-47
Clancy CE, 43:441-61
Colamarino SA, 44:399-421
Collins S, 44:297-323
Conney AH, 43:1-30
Coon MJ, 45:1-25
Correia MA, 45:439-64
Costa LG, 44:87-110
Coyle JT, 42:165-79

D

de Boer AG, 43:629-56
Denison MS, 43:309-34
Denker SP, 42:527-52
Ding X, 43:149-73
Drummond DC, 45:495-528
DuBois RN, 42:55-80
Ducruet AP, 45:725-50
Dudzinski DM, 46:235-76

E

Eichelbaum M, 43:285-307
Elling CE, 46:481-519
Elsayed Y, 43:199-231
Embree-Ku ME, 43:125-47
Esteller M, 45:629-56
Eudy JD, 42:181-208
Evans WE, 46:317-53

F

Fernandez EJ, 42:469-99
Finnell RH, 42:181-208
Fisone G, 44:269-96
Flanagan JU, 45:51-88
Fleming SL, 43:125-47
Foster BC, 45:203-26
Fredholm BB, 45:385-412
Frimurer TM, 46:481-519
Fromm MF, 43:285-307
Fukuto JM, 45:335-55
Fung H-L, 44:67-85

G

Gachet C, 46:277-300
Gage FH, 44:399-421
Gaillard PJ, 43:629-56
Gainetdinov RR, 43:261-84
Gandhi M, 44:499-523
Gelineau-van Waes J, 42:181-208
Ghyselinck NB, 46:451-80
Girault J-A, 44:269-96
Giri SN, 43:73-95
Go Y-M, 46:215-34
Gold MS, 44:371-97
Golding BT, 42:325-48
Gonzalez FJ, 46:41-64
Goodman JI, 42:501-25
Goodwin B, 42:1-23

Greenblatt RM, 44:499–523
 Greengard P, 44:269–96
 Greif D, 46:235–76
 Grenard P, 45:605–28
 Griffin RJ, 42:325–48
 Guengerich FP, 45:27–49
 Guo Z, 45:495–528

H
 Hall SJ, 43:125–47
 Hammock BD, 45:311–33
 Hansen JM, 46:215–34
 Hardcastle IR, 42:325–48
 Harden TK, 46:355–79
 Harris AL, 44:219–38
 Hayes JD, 45:51–88
 Hengstler JG, 43:485–520
 Hidemitsu T, 45:465–76
 Highfield Nickols H,
 44:559–609
 Hogg N, 42:585–600
 Holbro T, 44:195–217
 Holst B, 46:481–519
 Hough C, 45:269–90
 Hunter JC, 44:371–97
 Hurley LH, 43:359–79
 Hynes NE, 44:195–217

I
 Igarashi J, 46:235–76
 Ignarro LJ, 43:97–123

J
 Javitch JA, 42:437–67
 Johnson EM Jr, 44:451–74
 Johnson KJ, 43:125–47
 Jones DP, 46:215–34
 Jones JP, 45:477–94
 Jowsey IR, 45:51–88
 Juliano RL, 42:283–323
 Julien B, 45:605–28
 Jupe SC, 44:43–66

K
 Kamendulis LM, 44:239–67
 Kaminsky LS, 43:149–73
 Karplus PA, 44:325–47

Kass RS, 43:441–61
 Kauffman RE, 44:111–36
 Keefer LK, 43:585–607
 Kenakin T, 42:349–79
 Kim D, 45:27–49
 Kim G, 43:199–231
 Kim HP, 46:411–49
 Kim RB, 44:137–66
 Kinsel JF, 43:463–84
 Kirpotin DB, 45:495–528
 Kitteringham NR,
 45:177–202
 Klaunig JE, 44:239–67
 Klein TE, 42:113–33
 Kliewer SA, 42:1–23
 Kootstra NA, 43:413–39
 Krishnamurthy P, 46:381–410
 Kroetz DL, 45:413–38
 Kurokawa J, 43:441–61
 Kurzrock R, 45:357–84
 Kwon EJ, 43:125–47

L
 Lafontan M, 45:119–46
 Lai J, 44:371–97
 Lanier SM, 46:151–87
 Laufs U, 45:89–118
 Lazo JS, 45:725–50
 Lee W, 44:137–66
 Li AC, 46:1–39
 Liao JK, 45:89–118
 Lie DC, 44:399–421
 Liggett SB, 43:381–411
 Limbird LE, 44:559–609
 Liu X, 44:349–70
 Lolis E, 42:469–99
 Long CS, 45:657–87
 Lotersztajn S, 45:605–28
 Lughart S, 46:317–53

M
 Mackenzie PI, 44:1–25
 Mackie K, 46:101–22
 Maggs JL, 45:177–202
 Maliakal P, 42:25–54
 Mallat A, 45:605–28
 Mark M, 46:451–80

Marnett LJ, 42:55–80
 Martin TL, 44:297–323
 Masino SA, 45:385–412
 McCammon AJ, 43:31–45
 McGraw DW, 43:381–411
 McKinnon RA, 44:1–25
 Meng X, 42:25–54
 Michel JJ, 42:235–57
 Michel T, 46:235–76
 Miners JO, 44:1–25
 Ming G-I, 44:399–421
 Miranda KM, 45:335–55
 Mitchell MD, 45:657–87
 Möhler H, 44:475–98
 Moin K, 46:301–15
 Monga M, 43:199–231
 Morgan ET, 46:123–49
 Morrisseau C, 45:311–33
 Mundo-Paredes E, 45:439–64

N
 Nagy SR, 43:309–34
 Nairn AC, 44:269–96
 Napoli C, 43:97–123
 Nass R, 43:521–44
 Neu J, 42:381–408
 Nguyen T, 43:233–60
 Nishi A, 44:269–96
 Noble CO, 45:495–528

O
 Oesch F, 43:485–520
 Orlowski RZ, 46:189–213

P
 Palinski W, 46:1–39
 Park BK, 45:177–202
 Patel SR, 43:125–47
 Petralia RS, 43:335–58
 Pickett CB, 43:233–60
 Pirmohamed M,
 45:177–202
 Podgorski I, 46:301–15
 Poole LB, 44:325–47
 Pootoolal J, 42:381–408
 Porreca F, 44:371–97
 Potter WZ, 45:227–46

Prybylowski K, 43:335-58
Putney LK, 42:527-52

R

Rasoulpour RJ, 43:125-47
Redinbo MR, 42:1-23
Rees S, 44:43-66
Rettie AE, 45:477-94
Rezler EM, 43:359-79
Richardson TA, 46:123-49
Robidoux J, 44:297-323
Rosenkilde MM, 46:481-519
Rosengquist TH, 42:181-208
Rudolph U, 44:475-98
Ryter SW, 46:411-49

S

Sadeghi S, 45:439-64
Salahpour A, 42:409-35
Sameni M, 46:301-15
Sans N, 43:335-58
Sato H, 45:689-723
Sato M, 46:151-87
Sausville EA, 43:199-231
Schenk D, 43:545-84
Schnellmann RG,
44:349-70
Schoenfeld HA, 43:125-47
Schuetz JD, 46:381-410
Schwab M, 43:285-307
Scott GK, 45:495-528
Scott JD, 42:235-57
Selkoe DJ, 43:545-84
Senatorov VV, 45:269-90
Shapiro TA, 45:565-85

Sherratt PJ, 43:233-60
Shi L, 42:437-67
Shitara Y, 45:689-723
Simon V, 46:151-87
Simpson LL, 44:167-93
Sloane BF, 46:301-15
Small KM, 43:381-411
Smith PA, 44:1-25
Soldin OP, 44:87-110
Sondek J, 46:355-79
Song H, 44:399-421
Sorich MJ, 44:1-25
Standly S, 43:335-58
Straus SE, 43:463-84
Sugiyama Y, 45:689-723
Svenningsson P, 44:269-96
Svensson CI, 42:553-83
Sweatt JD, 42:135-63
Switzer CH, 45:335-55
Syversen T, 44:87-110

T

Tan CM, 44:559-609
Tateyama M, 43:441-61
Taylor SL, 42:99-112
Teixeira-Clerc F, 45:605-28
Thompson S, 43:125-47
Tibes R, 45:357-84
Tomizawa M, 45:247-68
Trent J, 45:357-84
Tsai G, 42:165-79

V

Vale WW, 44:525-58
van der Sandt ICJ, 43:629-56

Van Vleet T, 44:349-70
Vaugeois J-M, 45:385-412
Verma IM, 43:413-39
Vitalone A, 44:87-110
Vogt A, 45:725-50
Voorhees PM, 46:189-213

W

Wang LH, 44:451-74
Wang Q, 44:559-609
Watson RE, 42:501-25
Wehrens XHT, 43:441-61
Wei L-N, 43:47-72
Wenthold RJ, 43:335-58
Wess J, 44:423-50
White MA, 45:587-603
Williams DP, 45:177-202
Wink DA, 45:335-55
Wipf P, 45:725-50
Wise A, 44:43-66
Wong CF, 43:31-45
Wright GD, 42:381-408

Y

Yaksh TL, 42:553-83
Yang CS, 42:25-54
Yu A-M, 46:41-64

X

Xu F, 45:413-38

Z

Zhang J, 46:65-100
Zhang Y, 45:529-64
Zhang Z-Y, 42:209-34

CHAPTER TITLES, VOLUMES 42-46

Prefatory

PHARMACOLOGY

Cytochrome P450: Nature's Most Versatile
Biological Catalyst

MJ Coon

45:1-25

TOXICOLOGY

Induction of Drug-Metabolizing Enzymes:
A Path to the Discovery of Multiple
Cytochromes P450

AH Conney

43:1-30

General Topics in Pharmacology and Toxicology

Hormesis: The Dose-Response Revolution

EJ Calabrese,
LA Baldwin

43:175-97

Regulatory Mechanisms Controlling Gene
Expression Mediated by the Antioxidant
Response Element

T Nguyen,
PJ Sherratt,
CB Pickett

43:233-60

Voltage-Gated Sodium Channels and
Hyperalgesia

J Lai J, F Porreca,
JC Hunter,
MS Gold

44:371-97

RECEPTORS

Glutamatergic Mechanisms in
Schizophrenia

G Tsai, JT Coyle

42:165-79

Drug Efficacy at G Protein-Coupled
Receptors

T Kenakin

42:349-79

Dimerization: An Emerging Concept for G
Protein-Coupled Receptor Ontogeny and
Function

S Angers,
A Salahpour,
M Bouvier

42:409-35

The Binding Site of Aminergic G
Protein-Coupled Receptors: The
Transmembrane Segments and Second
Extracellular Loop
Retinoid Receptors and Their Coregulators

L Shi, JA Javitch
L-N Wei

42:437-67
43:47-72

Trafficking of NMDA Receptors	RJ Wenthold, K Prybylowski, S Standly, N Sans, RS Petralia	43:335-58
The Identification of Ligands at Orphan G-Protein Coupled Receptors	A Wise, SC Jupe, S Rees	44:43-66
ErbB Receptors: Directing Key Signaling Networks Throughout Life	T Holbro, NE Hynes	44:195-217
Voltage-Gated Sodium Channels and Hyperalgesia	J Lai J, F Porreca, JC Hunter, MS Gold	44:371-97
Membrane Trafficking of G Protein-Coupled Receptors	CM Tan, AE Brady, H Highfield Nickols, Q Wang, LE Limbird	44:559-609
Actions of Adenosine at Its Receptors in the CNS: Insights from Knockouts and Drugs	BB Fredholm, J-F Chen, SA Masino, J-M Vaugeois	45:385-412
Peroxisome Proliferator-Activated Receptors: How Their Effects on Macrophages Can Lead to the Development of a New Drug Therapy Against Atherosclerosis	AC Li, W Palinski	46:1-39
Cannabinoid Receptors as Therapeutic Targets	K Mackie	46:101-22
Accessory Proteins for G Proteins: Partners in Signaling	M Sato, JB Blumer, V Simon, SM Lanier	46:151-87
Regulation of Platelet Functions by P2 Receptors	C Gachet	46:277-300
Regulation of Phospholipase C Isozymes by Ras Superfamily GTPases	TK Harden, J Sondek	46:355-79
Function of Retinoid Nuclear Receptors: Lessons from Genetic and Pharmacological Dissections of the Retinoic Acid Signaling Pathway During Mouse Embryogenesis	M Mark, NB Ghyselinck, P Chambon	46:451-80

Molecular Mechanism of 7TM Receptor Activation—A Global Toggle Switch Model

TW Schwartz, TM Frimurer, B Holst, MM Rosenkilde, CE Elling 46:481-519

SIGNAL TRANSDUCTION

Cellular Mechanisms for the Repression of Apoptosis

CD Bortner, JA Cidlowski 42:259-81
LB Poole, A Karplus, A Claiborne 44:325-47
MA White, RGW Anderson 45:587-603

Protein Sulfenic Acids in Redox Signaling

Signaling Networks in Living Cells

Nuclear and Mitochondrial Compartmentation of Oxidative Stress and Redox Signaling

Regulation of Phospholipase C Isozymes by Ras Superfamily GTPases
CO as a Cellular Signaling Molecule

JM Hansen, Y Go, DP Jones 46:215-34
TK Harden J Sondek 46:355-79
HP Kim, SW Ryter, AMK Choi 46:411-49

SYNAPTIC FUNCTIONS

Molecular Psychology: Roles for the ERK

MAP Kinase Cascade in Memory

Identification of the Major Steps in

Botulinum Toxin Action

DARPP-32: An Integrator of

Neurotransmission

JP Adams, JD Sweatt 42:135-63
LL Simpson 44:167-93
P Svenningsson, A Nishi, G Fisone, J-A Girault, AC Nairn, P Greengard 44:269-96

Muscarinic Acetylcholine Receptor

Knockout Mice: Novel Phenotypes and Clinical Implications

J Wess 44:423-50

ION CHANNELS

Voltage-Gated Sodium Channels and Hyperalgesia

J Lai, F Porreca, JC Hunter, MS Gold 44:371-97

TRANSPORTERS

AKAP-Mediated Signal Transduction

JJC Michel, JD Scott 42:235-57

The Changing Face of the Na^+/H^+ Exchanger, NHE1: Structure, Regulation, and Cellular Actions	LK Putney, SP Denker, DL Barber	42:527-52
Monoamine Transporters: From Genes to Behavior	RR Gainetdinov, MG Caron	43:261-84
Genetic Polymorphisms of the Human MDR1 Drug Transporter	M Schwab, M Eichelbaum, MF Fromm	43:285-307
The <i>Caenorhabditis elegans</i> Dopaminergic System: Opportunities for Insights into Dopamine Transport and Neurodegeneration	R Nass, RD Blakely	43:521-44
The Role of Drug Transporters at the Blood-Brain Barrier	AG de Boer, ICJ van der Sandt, PJ Gaillard	43:629-56
Role of ABCG2/BCRP in Biology and Medicine	P Krishnamurthy, JD Schuetz	46:381-410

ENZYMES

Regulation of CYP3A Gene Transcription by the Pregnanate X Receptor	B Goodwin, MR Redinbo, SA Kliewer	42:1-23
Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112
The Biochemistry and Physiology of S-Nitrosothiols	N Hogg	42:585-600
Telomere Inhibition and Telomere Disruption as Processes for Drug Targeting	EM Rezler, DJ Bearss, LH Hurley	43:359-79
The Role of Calpain in Oncotic Cell Death	X Liu, T Van Vleet, RG Schnellmann	44:349-70
Mixed-Lineage Kinases: A Target for the Prevention of Neurodegeneration	LH Wang, CG Besirli, EM Johnson Jr.	44:451-74
Glutathione Transferases	JD Hayes, JU Flanagan, IR Jowsey	45:51-88

Non-Michaelis-Menten Kinetics in Cytochrome P450-Catalyzed Reactions	WM Atkins	45:291-310
Clinical Development of Histone Deacetylase Inhibitors	DC Drummond, CO Noble, DB Kirpotin, Z Guo, GK Scott, CC Benz	45:495-528
Evaluation of Drug-Drug Interaction in the Hepatobiliary and Renal Transport of Drugs	Y Shitara, H Sato, Y Sugiyama	45:689-723
The Regulation and Pharmacology of Endothelial Nitric Oxide Synthase	DM Dudzinski, J Igarashi, D Greif, T Michel	46:235-76
CHEMICAL AGENTS		
Inhibition of Carcinogenesis by Tea	CS Yang, P Malaiakal, X Meng	42:25-54
2,5-Nitric Oxide-Releasing Drugs	C Napoli, LJ Ignarro	43:97-123
Hexandione-Induced Testicular Injury	K Boekelheide, SL Fleming, T Allio, ME Embree-Ku, SJ Hall, KJ Johnson, EJ Kwon, SR Patel, RJ Rasoulpour, HA Schoenfeld, S Thompson	43:125-47
Progress Toward Clinical Application of the Nitric Oxide-Releasing Diazeniumdiolates	LK Keefer	43:585-607
Nitroxyl (HNO): Chemistry, Biochemistry, and Pharmacology	JM Fukuto, CH Switzer, KM Miranda, DA Wink	45:335-55
PEPTIDES AND PROTEINS		
Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112

BIOTRANSFORMATION

Regulation of CYP3A Gene Transcription by the Pregnanate X Receptor	B Goodwin, MR Redinbo, SA Kliewer	42:1-23
Human Extrahepatic Cytochromes P450: Function in Xenobiotic Metabolism and Tissue-Selective Chemical Toxicity in the Respiratory and Gastrointestinal Tracts	X Ding, LS Kaminsky	43:149-73
Predicting Human Drug Glucuronidation Parameters: Application of In Vitro and In Silico Modeling Approaches	JO Miners, PA Smith, MJ Sorich, RA McKinnon, PI Mackenzie	44:1-25
Oxidative Stress, Toxicology, and Pharmacology of CYP2E1	AA Caro, AI Cederbaum	44:27-42
Cytochrome P450 Activation of Arylamines and Heterocyclic Amines	D Kim, FP Guengerich	45:27-49
Formation and Toxicity of Anesthetic Degradation Products	MW Anders	45:147-76
The Role of Metabolic Activation in Drug-Induced Hepatotoxicity	BK Park, NR Kitteringham, JL Maggs, M Pirmohamed, DP Williams	45:177-202
Epoxide Hydrolases: Mechanisms, Inhibitor Designs, and Biological Roles	C Morisseau, BD Hammock	45:311-33
Tyrosine Kinase Inhibitors and the Dawn of Molecular Cancer Therapeutics	R Tibes, J Trent, R Kurzrock	45:357-84
Cytochrome P450 Ubiquitination: Branding for the Proteolytic Slaughter?	MA Correia, S Sadeghi, E Mundo-Paredes	45:439-64
Clinical and Toxicological Relevance of CYP2C9: Drug-Drug Interactions and Pharmacogenetics	AE Rettie, JP Jones	45:477-94
Cytochrome P450 and Xenobiotic Receptor Humanized Mice	FJ Gonzalez, A-M Yu	46:41-64

Human Flavin-Containing Monooxygenases	JR Cashman, J Zhang	46:65-100
Regulation of Drug-Metabolizing Enzymes and Transporters in Inflammation	AE Aitken, TA Richardson, ET Morgan	46:123-49
The Proteasome and Proteasome Inhibitors in Cancer Therapy	PM Voorhees, RZ Orlowski	46:189-213
PHARMACOKINETICS/TOXICOKINETICS		
The Integration of Pharmacokinetics and Pharmacodynamics: Understanding Dose-Response	SM Abdel-Rahman, RE Kauffman	44:111-36
Transporters and Renal Drug Elimination	W Lee, RB Kim	44:137-66
Natural Health Products and Drug Disposition	BC Foster, JT Arnason, CJ Briggs	45:203-26
Evaluation of Drug-Drug Interaction in the Hepatobiliary and Renal Transport of Drugs	Y Shitara, H Sato, Y Sugiyama	45:689-723
Role of ABCG2/BCRP in Biology and Medicine	P Krishnamurthy, JD Schuetz	46:381-410
CANCER AND CARCINOGENESIS		
Inhibition of Carcinogenesis by Tea	CS Yang, P Maliakal, X Meng	42:25-54
COX-2: A Target for Colon Cancer Prevention	LJ Marnett, RN DuBois	42:55-80
Glycopeptide Antibiotic Resistance	J Pootoolal, J Neu, GD Wright	42:381-408
Altered DNA Methylation: A Secondary Mechanism Involved in Carcinogenesis	JI Goodman, RE Watson	42:501-25
Signal Transduction-Directed Cancer Treatments	EA Sausville, Y Elsayed, M Monga, G Kim	43:199-231
The Role of Oxidative Stress in Carcinogenesis	JE Klaunig, LM Kamendulis	44:239-67

Proteasome Inhibition in Multiple Myeloma: Therapeutic Implication	D Chauhan, T Hideshima, KC Anderson	45:465-76
Aberrant DNA Methylation as a Cancer-Inducing Mechanism	M Esteller	45:629-56
Dual Specificity Protein Phosphatases: Therapeutic Targets for Cancer and Alzheimer's Disease	AP Ducruet, A Vogt, P Wipf, JS Lazo	45:725-50
Functional Imaging of Tumor Proteolysis	BF Sloane, M Sameni, I Podgorski, D Cavallo-Medved, K Moin	46:301-15
CLINICAL THERAPEUTICS		
Glycopeptide Antibiotic Resistance	J Pootoolal, J Neu, GD Wright	42:381-408
Complementary and Alternative Therapeutics: Rigorous Research is Needed to Support Claims	JF Kinsel, SE Straus	43:463-84
Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications	J Wess	44:423-50
Pleiotropic Effects of Statins	JK Liao, U Laufs	45:89-118
The Magic Bullets and Tuberculosis Drug Targets	Y Zhang	45:529-64
Molecular Mechanisms of Resistance in Antimalarial Chemotherapy: The Unmet Challenge	R Arav-Boger, TA Shapiro	45:565-85
Hepatic Fibrosis: Molecular Mechanisms and Drug Targets	S Lotersztajn, B Julien, F Teixeira-Clerc, P Grenard, A Mallat	45:605-28
Pharmacogenomics of Acute Leukemia	MH Cheok, S Lugthart, WE Evans	46:317-53
DRUG DEVELOPMENT SCIENCE		
Molecular Basis of Environmentally Induced Birth Defects	RH Finnell, J Gelineau-van Waes, JD Eudy, TH Rosenquist	42:181-208

Protein Tyrosine Phosphatases: Structure and Function, Substrate Specificity, and Inhibitor Development	Z-Y Zhang	42:209-34
Designing Inhibitors of Cyclin-Dependent Kinases	IR Hardcastle, BT Golding, RJ Griffin	42:325-48
Protein Flexibility and Computer-Aided Drug Design	CF Wong, JA McCammon	43:31-45
Gene Therapy with Viral Vectors	NA Kootstra, IM Verma	43:413-39
Biomarkers in Psychotropic Drug Development: Integration of Data across Multiple Domains	PR Bieck, WZ Potter	45:227-46

Systems

Neurogenesis in the Adult Brain: New Strategies for Central Nervous System Diseases	D Lie, H Song, SA Colamarino, G Ming, F Gage	44:399-421
---	--	------------

DEVELOPMENT AND AGING

Developmental Neuropathology of Environmental Agents	LG Costa, M Aschner, A Vitalone, T Syversen, OP Soldin	44:87-110
Neonicotinoid Insecticide Toxicology: Mechanisms of Selective Action	M Tomizawa, JE Casida	45:247-68

MUSCLE AND ADIPOSE TISSUE

β -Adrenergic Receptors and Regulation of Energy Expenditure: A Family Affair	J Robidoux, TL Martin, S Collins	44:297-323
Fat Cells: Afferent and Efferent Messages Define New Approaches to Treat Obesity	M Lafontan	45:119-46

IMMUNE SYSTEM/INFLAMMATION

Signal Transduction by Cell Adhesion Receptors and the Cytoskeleton: Functions of Integrins, Cadherins, Selectins, and Immunoglobulin-Superfamily Members	RL Juliano	42:283-323
---	------------	------------

Structure, Function, and Inhibition of Chemokines	EJ Fernandez, E Lolis	42:469-99
Innate Immune Responses to Microbial Poisons: Discovery and Function of the Toll-Like Receptors	B Beutler	43:609-28
Regulation and Inhibition of Arachidonic Acid (omega)-Hydroxylases and 20-HETE Formation	DL Kroetz, F Xu	45:413-38
CENTRAL NERVOUS SYSTEM		
Glutamatergic Mechanisms in Schizophrenia	G Tsai, JT Coyle	42:165-79
The Spinal Phospholipase-C Cyclooxygenase-Prostanoid Cascade in Nociceptive Processing	CI Svensson, TL Yaksh	42:553-83
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics	DJ Selkoe, D Schenk	43:545-84
Neurogenesis in the Adult Brain: New Strategies for Central Nervous System Diseases	D Lie, H Song, SA Colamarino, G Ming, F Gage	44:399-421
Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications	J Wess	44:423-50
Analysis of GABA _A Receptor Function and Dissection of the Pharmacology of Benzodiazepines and General Anesthetics Through Mouse Genetics	U Rudolph, H Möhler	44:475-98
CRF and CRF Receptors: Role in Stress Responsivity and Other Behaviors	TL Bale, WW Vale	44:525-58
Glyceraldehyde-3-Phosphate Dehydrogenase, Apoptosis, and Neurodegenerative Diseases	D-M Chuang, C Hough, VV Senatorov	45:269-90
Actions of Adenosine at its Receptors in the CNS: Insights from Knockouts and Drugs	BB Fredholm, J-F Chen, SA Masino, J-M Vaugeois	45:385-412
Dual Specificity Protein Phosphatases: Therapeutic Targets for Cancer and Alzheimer's Disease	AP Ducruet, A Vogt, P Wipf, JS Lazo	45:725-50

AUTONOMIC NERVOUS SYSTEM

Biochemical Mechanism of Nitroglycerin
Action and Tolerance: Is This Old
Mystery Solved?

H-L Fung

44:67-85

CARDIOVASCULAR SYSTEM

K^+ Channel Structure-Activity
Relationships and Mechanisms of
Drug-Induced QT Prolongation

CE Clancy,
J Kurokawa,
M Tateyama,
XHT Wehrens, RS Kass

43:441-61

Novel Angiogenic Signaling Pathways and
Vascular Targets
Pleiotropic Effects of Statins
Nitroxyl (HNO): Chemistry, Biochemistry,
and Pharmacology

R Bicknell, AL Harris
JK Liao, U Laufs44:219-38
45:89-118JM Fukuto, CH Switzer,
KM Miranda,
DA Wink

45:335-55

The Cardiac Fibroblast: Therapeutic Target
in Myocardial Remodeling and Failure

RD Brown,
SK Ambler,
MD Mitchell, CS Long

45:657-87

PULMONARY SYSTEM

Cytokine Modulators as Novel Therapies
for Asthma
Novel Pharmacological Approaches to
Manage Interstitial Lung Fibrosis in the
Twenty-First Century

PJ Barnes

42:81-98

SN Giri

43:73-95

Miscellaneous

TECHNIQUES

Challenges for Biomedical Informatics and
Pharmacogenomics

RB Altman, TE Klein

42:113-33

ENVIRONMENTAL TOXICITY

Challenging Dogma: Thresholds for
Genotoxic Carcinogens? The Case of
Vinyl Acetate

JG Hengstler,
MS Bogdanffy,
HM Bolt, F Oesch

43:485-520

Neonicotinoid Insecticide Toxicology:
Mechanisms of Selective Action

M Tomizawa,
JE Casida

45:247-68

